Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Vertex Pharmaceuticals IncVRTX | $527.67 | Strong Buy | $615.00 | +16.55% | a day ago | |
Analyst RankingTop 10% #531 out of 5523 analysts Average Return+15.34% Win Rate53%58 out of 110 Risk vs RewardPoor Good Analyst ColorUBS's Michael Yee raised their price target on Vertex Pharmaceuticals (NASDAQ: VRTX) by 5.1% from $585 to $615 on 2026/09/28. The analyst maintained their Strong Buy rating on the stock. Raising their price target, Yee looked ahead and opined that Vertex Pharmaceuticals' key near-term catalyst is the early-2027 interim Phase 3 readout for inaxaplin in APOL1-mediated kidney disease. The cautioned that success will require statistically significant improvements in both proteinuria and eGFR slope. Success could validate a potential $2B to $3B severe-primary AMKD opportunity, Yee noted. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.